The CDK1/TFCP2L1/ID2 cascade offers a novel combination therapy strategy in a preclinical model of bladder cancer
0
조회
0
다운로드
3
인용
0
참고문헌
초록
Aberrant activation of embryogenesis-related molecular programs in urothelial bladder cancer (BC) is associated with stemness features related to oncogenic dedifferentiation and tumor metastasis. Recently, we reported that overexpression of transcription factor CP2-like protein-1 (TFCP2L1) and its phosphorylation at Thr177 by cyclin-dependent kinase-1 (CDK1) play key roles in regulating bladder carcinogenesis. However, the clinical relevance and therapeutic potential of this novel CDK1-TFCP2L1 molecular network remain elusive. Here, we demonstrated that inhibitor of DNA binding-2 (ID2) functions as a crucial mediator by acting as a direct repressive target of TFCP2L1 to modulate the stemness features and survival of BC cells. Low ID2 and high CDK1 expression were significantly associated with unfavorable clinical characteristics. TFCP2L1 downregulated ID2 by directly binding to its promoter region. Consistent with these findings, ectopic expression of ID2 or treatment with apigenin, a chemical activator of ID2, triggered apoptosis and impaired the proliferation, suppressed the stemness features, and reduced the invasive capacity of BC cells. Combination treatment with the specific CDK1 inhibitor RO-3306 and apigenin significantly suppressed tumor growth in an orthotopic BC xenograft animal model. This study demonstrates the biological role and clinical utility of ID2 as a direct target of the CDK1-TFCP2L1 pathway for modulating the stemness features of BC cells.
Abstract
Aberrant activation of embryogenesis-related molecular programs in urothelial bladder cancer (BC) is associated with stemness features related to oncogenic dedifferentiation and tumor metastasis. Recently, we reported that overexpression of transcription factor CP2-like protein-1 (TFCP2L1) and its phosphorylation at Thr177 by cyclin-dependent kinase-1 (CDK1) play key roles in regulating bladder carcinogenesis. However, the clinical relevance and therapeutic potential of this novel CDK1-TFCP2L1 molecular network remain elusive. Here, we demonstrated that inhibitor of DNA binding-2 (ID2) functions as a crucial mediator by acting as a direct repressive target of TFCP2L1 to modulate the stemness features and survival of BC cells. Low ID2 and high CDK1 expression were significantly associated with unfavorable clinical characteristics. TFCP2L1 downregulated ID2 by directly binding to its promoter region. Consistent with these findings, ectopic expression of ID2 or treatment with apigenin, a chemical activator of ID2, triggered apoptosis and impaired the proliferation, suppressed the stemness features, and reduced the invasive capacity of BC cells. Combination treatment with the specific CDK1 inhibitor RO-3306 and apigenin significantly suppressed tumor growth in an orthotopic BC xenograft animal model. This study demonstrates the biological role and clinical utility of ID2 as a direct target of the CDK1-TFCP2L1 pathway for modulating the stemness features of BC cells.
참고문헌 (42)
- Huang, H. M., "Tumor heterogeneity and the potential role of liquid biopsy in bladder cancer", Cancer Commun. (Lond. ), 41, pp.91~108 (2021)
- Sung, H., "Global Cancer Statistics 2020 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J. Clin, 71, pp.209~249 (2021)
- Rosenberg, J. E., "Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy : a single-arm, multicentre, phase 2 trial", Lancet, 387, pp.1909~19201909 (2016)
- Sanli, O., "Bladder cancer", Nat. Rev. Dis. Prim, 3, pp.17022~ (2017)
- Yin Yue-Wei, "RBM24 exacerbates bladder cancer progression by forming a Runx1t1", TCF4, Experimental and Molecular Medicine, pp.2021, 53[DOI]
- Lambert, S. A., "The human transcription factors", Cell, 172, pp.650~665 (2018)
- Ooki, A., "YAP1 and COX2 coordinately regulate urothelial cancer stem-like cells", Cancer Res, 78, pp.168~181 (2018)
- Pan, G., "EMT-associated microRNAs and their roles in cancer stemness and drug resistance", Cancer Commun. (Lond. ), 41, pp.199~217 (2021)
- Malta, "Machine learning identifies stemness features associated with oncogenic dedifferentiation", Cell, 173, pp.338~354.e315 (2018)
- Heo, J., "Phosphorylation of TFCP2L1 by CDK1 is required for stem cell pluripotency and bladder carcinogenesis", EMBO Mol. Med, 12, pp.e10880~ (2020)
- Shin, K., "Hedgehog signaling restrains bladder cancer progression by eliciting stromal production of urothelial differentiation factors", Cancer Cell, 26, pp.521~533 (2014)
- The Cancer Genome Atlas Research, N., "Comprehensive molecular characterization of urothelial bladder carcinoma", Nature, 507, pp.315~ (2014)
- Robertson, A. G., "Comprehensive molecular characterization of muscleinvasive bladder cancer", Cell, 171, pp.540~556.e525 (2017)
- Tang, Z., "GEPIA : a web server for cancer and normal gene expression profiling and interactive analyses", Nucleic Acids Res, 45, pp.W98~W102 (2017)
- Berger, A. H., "High-throughput phenotyping of lung cancer somatic mutations", Cancer Cell, 30, pp.214~228 (2016)
- Kim, Y., "Small hypoxia-primed mesenchymal stem cells attenuate graftversus-host disease", Leukemia, 32, pp.2672~2684 (2018)
- Lim, J., "Glutathione dynamics determine the therapeutic efficacy of mesenchymal stem cells for graft-versus-host disease via CREB1-NRF2 pathway", Sci. Adv, 6, pp.eaba1334~ (2020)
- Lim, J., "Small-sized mesenchymal stem cells with high glutathione dynamics show improved therapeutic potency in graft-versus-host disease", Clin. Transl. Med, 11, pp.e476~ (2021)
- Heo, J., "Sirt1 regulates DNA methylation and differentiation potential of embryonic stem cells by antagonizing Dnmt3l", Cell Rep, 18, pp.1930~1945 (2017)
- Jeong, E. M., "Real-time monitoring of Glutathione in living cells reveals that high glutathione levels are required to maintain stem cell function", Stem Cell Rep, 10, pp.600~614 (2018)
- Lee, S., "Ascorbic acid 2-glucoside stably promotes the primitiveness of embryonic and mesenchymal stem cells through ten-eleven translocation-and cAMP-responsive element-binding protein-1-dependent mechanisms", Antioxid. Redox Signal, 32, pp.35~59 (2020)
- Ryu, C. M., "Longitudinal intravital imaging of transplanted mesenchymal stem cells elucidates their functional integration and therapeutic potency in an animal model of interstitial cystitis", bladder pain syndrome, 2018, pp.8, 5610~5624
- Choi, W., "Identification of distinct basal and luminal subtypes of muscleinvasive bladder cancer with different sensitivities to frontline chemotherapy", Cancer Cell, 25, pp.152~165 (2014)
- Nickerson, M. L., "Molecular analysis of urothelial cancer cell lines for modeling tumor biology and drug response", Oncogene, 36, pp.35~46 (2017)
- Vrijens, K., "Identification of small molecule activators of BMP signaling", PLoS One, 8, pp.e59045~ (2013)
- Yan, X., "Apigenin in cancer therapy : anti-cancer effects and mechanisms of action", Cell Biosci, 7, pp.50~ (2017)
- Wells, C. I., "Quantifying CDK inhibitor selectivity in live cells", Nat. Commun, 11, pp.2743~ (2020)
- Roschger, C., "The Id-protein family in developmental and cancerassociated pathways", Cell Commun. Signal, 15, pp.7~ (2017)
- Grcevic, D., "Bone morphogenetic proteins and receptors are over-expressed in bone-marrow cells of multiple myeloma patients and support myeloma cells by inducing ID genes", Leuk. Res, 34, pp.742~751 (2010)
- Rockman, S. P., "Id2 is a target of the beta-catenin", T cell factor pathway in colon carcinoma, 2001, pp.276, 45113~45119
- Lasorella, A., "Id2 is a retinoblastoma protein target and mediates signalling by Myc oncoproteins", Nature, 407, pp.592~598 (2000)
- Ahlqvist, K., "Expression of Id proteins is regulated by the Bcl-3 proto-oncogene in prostate cancer", Oncogene, 32, pp.1601~1608 (2013)
- Ghisi, M., "Id2 and E proteins orchestrate the initiation and maintenance of MLL-rearranged acute myeloid leukemia", Cancer Cell, 30, pp.59~74 (2016)
- Nigten, J., "ID1 and ID2 are retinoic acid responsive genes and induce a G0", G1accumulation in acute promyelocytic leukemia cells, 2005, pp.19, 799~805
- Stighall, M., "High ID2 protein expression correlates with a favourable prognosis in patients with primary breast cancer and reduces cellular invasiveness of breast cancer cells", Int. J. Cancer, 115, pp.403~411 (2005)
- Itahana, Y., "Role of Id-2 in the maintenance of a differentiated and noninvasive phenotype in breast cancer cells", Cancer Res, 63, pp.7098~7105 (2003)
- Kim Dae-Seok, "Alternate therapeutic pathways for PARP inhibitors and potential mechanisms of resistance", Experimental and Molecular Medicine, 53, pp.1~10 (2021), 생화학분자생물학회[DOI]
- Salmani, J. M. M., "Apigenin’s anticancer properties and molecular mechanisms of action : Recent advances and future prospectives", Chin. J. Nat. Med, 15, pp.321~329 (2017)
- Hedegaard, J., "Comprehensive transcriptional analysis of early-stage urothelial carcinoma", Cancer Cell, 30, pp.27~42 (2016)
- Sjodahl, G., "A molecular taxonomy for urothelial carcinoma", Clin. Cancer Res, 18, pp.3377~3386 (2012)
- Wu, C. X., "Blocking CDK1", PDK1, Theranostics, pp.2018, 8[DOI]
- Yang, W., "Accumulation of cytoplasmic Cdk1 is associated with cancer growth and survival rate in epithelial ovarian cancer", Oncotarget, 7, pp.49481~49497 (2016)